Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 18,200 shares of the company’s stock after selling 427 shares during the quarter. Securian Asset Management Inc.’s holdings in Moderna were worth $757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB lifted its stake in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in shares of Moderna in the 4th quarter valued at $37,000. Venturi Wealth Management LLC lifted its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after purchasing an additional 388 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Up 0.9 %

Shares of MRNA opened at $34.62 on Friday. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The firm has a 50-day moving average price of $35.94 and a 200 day moving average price of $47.37. The firm has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on MRNA shares. Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Morgan Stanley reduced their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.